Immuneering Stock Forecast, Price & News

+1.08 (+4.26 %)
(As of 09/23/2021 02:37 PM ET)
Today's Range
50-Day Range N/A
52-Week Range
Volume643 shs
Average Volume165,030 shs
Market Capitalization$686.06 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter.

Immuneering logo

About Immuneering

Immuneering Corporation is a biopharmaceutical company advancing a pipeline of oncology and neuroscience product candidates. The company's product candidate includes IMM-1-104. Immuneering Corporation is based in CAMBRIDGE, Mass.


Immuneering (NASDAQ:IMRX) Shares Up 5.9%
Immuneering (NASDAQ:IMRX) Shares Up 5.9%
September 21, 2021 |
Immuneering Announces Inclusion in the Russell 2000® Index
Immuneering Announces Inclusion in the Russell 2000® Index
September 20, 2021 |
Immuneering (NASDAQ:IMRX)  Shares Down 12.2%
Immuneering (NASDAQ:IMRX) Shares Down 12.2%
September 20, 2021 |
Immuneering (NASDAQ:IMRX) Sees Strong Trading Volume
Immuneering (NASDAQ:IMRX) Sees Strong Trading Volume
September 14, 2021 |
Immuneering (NASDAQ:IMRX) Stock Price Up 11.9%
Immuneering (NASDAQ:IMRX) Stock Price Up 11.9%
September 13, 2021 |
Immuneering (NASDAQ:IMRX) Shares Gap Down to $24.27
Immuneering (NASDAQ:IMRX) Shares Gap Down to $24.27
September 10, 2021 |
Immuneering (NASDAQ:IMRX)  Shares Down 6.4%
Immuneering (NASDAQ:IMRX) Shares Down 6.4%
September 7, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.80 out of 5 stars

Medical Sector

782nd out of 1,351 stocks

Pharmaceutical Preparations Industry

381st out of 664 stocks

Analyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Immuneering (NASDAQ:IMRX) Frequently Asked Questions

Is Immuneering a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immuneering in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Immuneering stock.
View analyst ratings for Immuneering
or view top-rated stocks.

What stocks does MarketBeat like better than Immuneering?

Wall Street analysts have given Immuneering a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Immuneering wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Immuneering's next earnings date?

Immuneering is scheduled to release its next quarterly earnings announcement on Thursday, December 9th 2021.
View our earnings forecast for Immuneering

How were Immuneering's earnings last quarter?

Immuneering Corp (NASDAQ:IMRX) posted its earnings results on Thursday, September, 9th. The company reported ($1.61) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.66) by $0.05.
View Immuneering's earnings history

What price target have analysts set for IMRX?

4 Wall Street analysts have issued 1 year price targets for Immuneering's stock. Their forecasts range from $39.00 to $50.00. On average, they expect Immuneering's share price to reach $43.67 in the next twelve months. This suggests a possible upside of 66.3% from the stock's current price.
View analysts' price targets for Immuneering
or view top-rated stocks among Wall Street analysts.

When did Immuneering IPO?

(IMRX) raised $105 million in an initial public offering on Friday, July 30th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities served as the underwriters for the IPO.

What is Immuneering's stock symbol?

Immuneering trades on the NASDAQ under the ticker symbol "IMRX."

When did the company's quiet period expire?

Immuneering's quiet period expired on Wednesday, September 8th. Immuneering had issued 7,500,000 shares in its initial public offering on July 30th. The total size of the offering was $112,500,000 based on an initial share price of $15.00. During the company's quiet period, underwriters and any insiders involved in the IPO were prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Immuneering?

Shares of IMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immuneering's stock price today?

One share of IMRX stock can currently be purchased for approximately $26.25.

How much money does Immuneering make?

Immuneering has a market capitalization of $680.87 million.

How many employees does Immuneering have?

Immuneering employs 2,021 workers across the globe.

What is Immuneering's official website?

The official website for Immuneering is

How can I contact Immuneering?

The company can be reached via phone at 617-500-8080 or via email at [email protected].

This page was last updated on 9/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.